Bone Biologics Stock Analysis

BBLG -  USA Stock  

USD 2.83  0.24  9.27%

The big decline in price over the last few months for Bone Biologics Corp could raise concerns from shareholders as the firm it trading at a share price of 2.83 on 163,187 in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Bone Biologics Corp or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 9.85. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Bone Biologics partners.
Continue to Trending Equities.

Bone Biologics Stock Analysis 

 
Refresh
The Bone Biologics stock analysis report makes it easy to digest most publicly released information about Bone Biologics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Bone Biologics Stock analysis module also helps to analyze the Bone Biologics price relationship with some important fundamental indicators such as market cap and management efficiency.

Bone Biologics Stock Analysis Notes

About 70.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.15. Bone Biologics Corp had not issued any dividends in recent years. The entity had a split on the 13th of October 2021. Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. For more info on Bone Biologics Corp please contact Stephen Neve at 781 552 4452 or go to https://www.bonebiologics.com.

Bone Biologics Corp Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bone Biologics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bone Biologics Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bone Biologics Corp generated a negative expected return over the last 90 days
Bone Biologics Corp has high historical volatility and very poor performance
Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years
Bone Biologics Corp was previously known as Bone Biologics Corp and was traded on NASDAQ Exchange under the symbol BBLGW.
Net Loss for the year was (1.89 M).
Bone Biologics Corp currently holds about 3.37 K in cash with (1.17 M) of positive cash flow from operations.
Bone Biologics Corp has a frail financial position based on the latest SEC disclosures
Roughly 70.0% of the company shares are held by company insiders
Latest headline from www.investing.com: US stocks mixed at close of trade Dow Jones Industrial Average down 0.45 percent By Investing.com - Investing.com

Bone Biologics Corp Upcoming and Recent Events

Earnings reports are used by Bone Biologics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bone Biologics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report21st of February 2022
Next Earnings Report20th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End21st of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Bone Biologics Largest EPS Surprises

Earnings surprises can significantly impact Bone Biologics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
View All Earnings Estimates

Bone Biologics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Bone Biologics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Bone Biologics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Bone Biologics Corp specific information freely available to individual and institutional investors to make a timely investment decision.
22nd of December 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
1st of November 2021
Unclassified Corporate Event
View
19th of October 2021
Financial Statements and Exhibits. Other Events
View
15th of October 2021
Financial Statements and Exhibits. Other Events. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Entry into a Material Definitive Agreement
View
7th of June 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
17th of May 2021
Other Events
View

Bone Biologics Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 30.84 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bone Biologics's market, we take the total number of its shares issued and multiply it by Bone Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Bone Biologics Profitablity

Bone Biologics' profitability indicators refer to fundamental financial ratios that showcase Bone Biologics' ability to generate income relative to its revenue or operating costs. If, let's say, Bone Biologics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Bone Biologics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Bone Biologics' profitability requires more research than a typical breakdown of Bone Biologics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(604.98) (620.90) 
Return on Average Equity 0.13  0.13 
Return on Invested Capital 0.64  0.69 

Management Efficiency

The current year Return on Invested Capital is expected to grow to 0.69, whereas Return on Average Assets are forecasted to decline to (620.90) . Bone Biologics Current Assets are projected to decrease significantly based on the last few years of reporting. The past year's Current Assets were at 27,744.3. The current year Assets Non Current is expected to grow to 46.18, whereas Return on Average Assets are forecasted to decline to (620.90) . Bone Biologics management efficiency ratios could be used to measure how well bone biologics corp manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2022
Book Value per Share(4.23) (4.56) 
Enterprise Value over EBIT(112.50) (115.46) 
Enterprise Value over EBITDA(112.74) (115.71) 
Price to Book Value(7.73) (8.34) 
Tangible Assets Book Value per Share 0.0099  0.0102 
Enterprise Value118.8 M105.3 M
Tangible Asset Value27.7 K28.5 K

Technical Drivers

As of the 26th of January, Bone Biologics shows the mean deviation of 5.5, and Risk Adjusted Performance of (0.029905). Bone Biologics Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Bone Biologics Corp, which can be compared to its rivals. Please confirm Bone Biologics Corp maximum drawdown, and the relationship between the information ratio and downside variance to decide if Bone Biologics Corp is priced correctly, providing market reflects its regular price of 2.83 per share. Please also double-check Bone Biologics Corp total risk alpha, which is currently at 0.2671 to validate the company can sustain itself at a future point.

Bone Biologics Corp Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Simple Moving Average indicator is calculated by adding the closing price of Bone Biologics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Bone Biologics Corp short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

Bone Biologics Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bone Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Bone Biologics Technical and Predictive Indicators

Bone Biologics Forecast Models

Bone Biologics time-series forecasting models is one of many Bone Biologics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bone Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Bone Biologics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bone Biologics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bone Biologics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Bone Biologics. By using and applying Bone Biologics Stock analysis, traders can create a robust methodology for identifying Bone Biologics entry and exit points for their positions.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Bone Biologics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Fundamentals Comparison Now

   

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Module
Continue to Trending Equities. Note that the Bone Biologics Corp information on this page should be used as a complementary analysis to other Bone Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Bone Biologics Stock analysis

When running Bone Biologics Corp price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Bone Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Bone Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.